N-methyl-D-aspartate receptor glycine-B co-agonist site (NMDAR glycine site)

The N-methyl-D-aspartate (NMDA) receptor glycine-B co-agonist site is a critical regulatory locus located on the GluN1 (NR1) subunit of the NMDA receptor complex. Unlike the inhibitory glycine receptor, this site is strychnine-insensitive and must be occupied by an endogenous co-agonist, such as glycine or D-serine, for the receptor's ion channel to open in response to glutamate. This obligatory co-activation mechanism makes the glycine-B site a fundamental modulator of synaptic plasticity, long-term potentiation, and excitatory neurotransmission throughout the central nervous system (NIH, StatPearls). Dysregulation of this site is heavily implicated in the pathophysiology of schizophrenia, where NMDA receptor hypofunction contributes to cognitive and negative symptoms, and in major depressive disorder, where modulation can induce rapid antidepressant effects (PubMed, UniProt). Therapeutic strategies include using partial agonists like D-cycloserine to enhance cognition or antagonists to provide neuroprotection against excitotoxic injury during stroke or chronic neurodegeneration. Modern drug development continues to target this site with novel modulators like rapastinel to treat treatment-resistant depression and other neuropsychiatric conditions (IUPHAR/BPS Guide to Pharmacology).

Other names

Strychnine-insensitive glycine binding siteGlycine-B siteNMDA receptor glycine siteGluN1 glycine binding siteNR1 glycine site

Drugs targeting this site act as agonists or partial agonists to enhance NMDA receptor function, which is required for channel opening alongside glutamate binding. Conversely, antagonists or negative allosteric modulators at this site inhibit receptor activity to prevent excitotoxicity or provide analgesia. Some agents act as glycine transporter inhibitors (e.g., sarcosine) to indirectly increase synaptic glycine concentrations at this site.